Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-07
2006-02-07
Tsang, Cecilia J. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S210180, C514S227800, C514S231800, C514S252110, C514S316000, C514S422000, C544S060000, C544S078000, C544S357000, C546S189000, C548S518000, C548S950000, C548S962000
Reexamination Certificate
active
06995151
ABSTRACT:
Selective MMP-13 inhibitors are isophthalic acid derivatives of the formulawherein:R1, R2, and R3independently are hydrogen, halo, hydroxy, C1–C6alkyl, C1–C6alkoxy, C2–C6alkenyl, C2–C6alkynyl, NO2, NR4R5, CN, or CF3;E is independently O or S;A and B independently are OR4or NR4R5;each R4and R5independently are H, C1–C6alkyl, C2–C6alkenyl, C2–C6alkynyl, (CH2)naryl, (CH2)ncycloalkyl, (CH2)nheteroaryl, or R4and R5when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;n is 0 to 6;or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.
REFERENCES:
patent: 5130317 (1992-07-01), Baader et al.
patent: 5260323 (1993-11-01), Baader et al.
patent: 5519038 (1996-05-01), Baader et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 2003/0229103 (2003-12-01), Weithmann et al.
patent: 2082076 (1993-05-01), None
patent: 0418797 (1991-03-01), None
patent: 0463592 (1992-01-01), None
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 5193260 (1993-08-01), None
patent: WO9905148 (1999-02-01), None
patent: 0009485 (2000-02-01), None
patent: WO0105389 (2001-01-01), None
patent: 0112611 (2001-02-01), None
patent: WO 01/63244 (2001-08-01), None
patent: 0234726 (2002-05-01), None
patent: 0234753 (2002-05-01), None
patent: 02064368 (2002-08-01), None
patent: 02064371 (2002-08-01), None
patent: 03049738 (2003-06-01), None
Chen JM et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, Journal of the American Chemical Society 2000; 122:9648-9654.
Boger, DL et al., Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin. alpha.V. beta. 3, Journal of the American Chemical Society 2001; 123:1280-1288.
Silletti, S. et al, “Disruption of matrix metalloproteinase 2 binding to integrin alpha. v. beta. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo”, Proceeding of the National Academy of Sciences of the United States of America 2001; 98(1)119-124.
Milton J. et al, “Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2”, Bioorganic & Medicinal Chemistry Letters, Oxford, GB 1998; 8:2623-2628.
Montana, John et al, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361.
Clark, Ian, et al, “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25.
Chen, James, et al, “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, 122; pp 9648-9654.
International Search Report for PCT/IB02/00344, which corresponds to US10/075,918.
Office Action mailed Jun. 16, 2003 in U.S. Appl. No. 10/264,764.
Ye, et al., “Catalytic Domains of Matrix Metalloproteinases: A Molecular Biology Approach to Drug Discovery”, Curr.Med.Chem., 1996; 3:407-418.
LoveJoy, et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biol., 1999; 6:217-221.
Moy, et al., High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor , J. Mol. Biol., 2000; 302:671-689.
Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3):761-768.
Neuhold, et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001; 107: 35-44.
Dahlberg, et al., Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproteinase 1), Arthrit. & Rheum., 2000; 43(3): 673-682.
Billinghurst, et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleuken-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000; 43(3):664-672.
Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997; 99:1534-1545.
Hirota, et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]-pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative coupling”, Heterocycles, 1994; 37(1):563-570.
Barvian Nicole Chantel
Connor David Thomas
Dyer Richard Dennis
Johnson Adam Richard
Patt William Chester
Ashbrook Charles W.
Crissey Todd M.
Oh Taylor Victor
Purchase, Jr. Claude F.
Tsang Cecilia J.
LandOfFree
Isophthalic acid derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isophthalic acid derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isophthalic acid derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683826